The emerging roles and mechanism of N6-methyladenosine (m6A) modifications in urologic tumours progression

Wenhao Zhu; Renshan Zhao; Xiaomin Guan; Xu Wang

doi:10.3389/fphar.2023.1192495

The emerging roles and mechanism of N6-methyladenosine (m⁶A) modifications in urologic tumours progression

Front Pharmacol. 2023 May 22:14:1192495. doi: 10.3389/fphar.2023.1192495. eCollection 2023.

Authors

Wenhao Zhu¹, Renshan Zhao¹, Xiaomin Guan¹, Xu Wang¹

Affiliation

¹ Cancer Center, The First Hospital of Jilin University, Changchun, China.

Abstract

Prostate cancer (PCa), bladder cancer (BC), and renal cell cancer (RCC) are the most common urologic tumours in males. N6-methyladenosine (m⁶A), adenosine N6 methylation, is the most prevalent RNA modification in mammals. Increasing evidence suggests that m⁶A plays a crucial role in cancer development. In this review, we comprehensively analyzed the influence of m⁶A methylation on Prostate cancer, bladder cancer, and renal cell cancer and the relationship between the expression of relevant regulatory factors and their development and occurrence, which provides new insights and approaches for the early clinical diagnosis and targeted therapy of urologic malignancies.

Keywords: N6-methyladenosine; coding RNAs; epitranscriptome; non-coding RNAs; posttranscriptional modification; urologic tumours.

Publication types

Review